Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer
Open Access
- 18 July 2024
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-11
Abstract
Background: Immune checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1) antibodies, have achieved breakthrough results in improving long-term survival rates in lung cancer. Although high levels of PD-L1 expression and tumor mutational burden have emerged as pivotal biomarkers, not all patients derive lasting benefits, and resistance to immune checkpoint blockade remains a prevalent issue. Comprehending the immunological intricacies of lung cancer is crucial for uncovering the mechanisms that govern responses and resistance to immunomodulatory treatments. This study aimed to explore the potential of peripheral immune markers in predicting treatment efficiency among lung cancer patients undergoing PD-1/PD-L1 checkpoint inhibitors. Methods: This study enrolled 71 lung cancer patients undergoing PD-1/PD-L1 inhibitor therapy and 20 healthy controls. Immune cell subsets (CD4 + T cells, CD8 + T cells, B cells, NK cells, and NKT cells), phenotypic analysis of T cells and B cells, and PMA/Ionomycin-stimulated lymphocyte function assay were conducted. Results: Lung cancer patients exhibited significant alterations in immune cell subsets, notably an increased percentage of Treg cells. Post-treatment, there were substantial increases in absolute numbers of CD3 + T cells, CD8 + T cells, and NKT cells, along with heightened HLA-DR expression on CD3 + T and CD8 + T cells. Comparison between complete remission and non-complete remission (NCR) groups showed higher Treg cell percentages and HLA-DR + CD4 + T cells in the NCR group. Conclusion: The study findings suggest potential predictive roles for immune cell subsets and phenotypes, particularly Treg cells, HLA-DR + CD4 + T cells, and naïve CD4 + T cells, in evaluating short-term PD-1/PD-L1 therapy efficacy for lung cancer patients. These insights offer valuable prospects for personalized treatment strategies and underscore the importance of immune profiling in lung cancer immunotherapy.Keywords
Funding Information
- Health Commission of Hubei Province (WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010, WJ2023M010)
- State Key Laboratory of Materials Processing and Die and Mould Technology (P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014, P2023-014)
This publication has 42 references indexed in Scilit:
- The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancerTranslational Oncology, 2020
- Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitorsCancer Immunology, Immunotherapy, 2020
- Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancerLung Cancer, 2018
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumabLung Cancer, 2017
- Regulatory T cells in malignant pleural effusions subsequent to lung carcinoma and their impact on the course of the diseaseImmunobiology, 2017
- Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humansCancer Immunology, Immunotherapy, 2016
- Innate and adaptive immune cells in the tumor microenvironmentNature Immunology, 2013
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic SignaturesImmunity, 2013
- Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancerGeneral Thoracic and Cardiovascular Surgery, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009